HGI 004
Alternative Names: HGI-004Latest Information Update: 31 Mar 2023
At a glance
- Originator Shenzhen Hemogen
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 08 Mar 2023 Preclinical trials in Unspecified in China (unspecified route), prior to March 2023 (Shenzhen Hemogen pipeline, March 2023)